Four venture capital firms have raised more than $1bn in new money for life science and health care investments, which could be divided among a large number of biotechnology companies if a recent trend toward smaller funding rounds continues for US and EU firms.
There's been some concern during the past few record-breaking years of biotech venture capital financing about the decline in seed and early-stage funding rounds for companies at the beginning stages of drug development, but recent VC deals seem to suggest a reversal of that trend
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?